Sign in with your email address username.


[Department of Error] Department of Error

Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383: 2222–31—In this Article (April 1), in the Results section, the third sentence of the sixth paragraph should have read, “The dolutegravir group had significantly fewer LDL values of grade 2 or higher than did the darunavir plus ritonavir group (5% vs 16%; p=0·0001), against a pre-specified p value threshold of 0·045 (two-sided; appendix).” This correction has been made to the online version of the Article as of June 26, 2015.